Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Stem Cell Research

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 43 articles:
HTML format



Single Articles


    November 2021
  1. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.
    PubMed    


  2. HOSOI H, Matsuyama Y, Murata S, Mushino T, et al
    Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 16:1-4. doi: 10.1080/10428194.2021.2005047.
    PubMed    


  3. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.
    PubMed    


  4. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available


    October 2021
  5. ALHOMOUD M, Williams A, Magro C, Van Besien K, et al
    Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
    Leuk Lymphoma. 2021 Oct 20:1-5. doi: 10.1080/10428194.2021.1992625.
    PubMed    


  6. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    PubMed     Abstract available


  7. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.
    PubMed    


    September 2021
  8. PAVIGLIANITI A, Sestili S, Bianchessi A, Memoli M, et al
    Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984460.
    PubMed     Abstract available


  9. SAWALHA Y, Radivoyevitch T, Jia X, Tullio K, et al
    The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2021 Sep 15:1-9. doi: 10.1080/10428194.2021.1978085.
    PubMed     Abstract available


    August 2021
  10. PATEL SA, Dalela D, Fan AC, Lloyd MR, et al
    Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.
    Leuk Lymphoma. 2021 Aug 19:1-9. doi: 10.1080/10428194.2021.1966779.
    PubMed     Abstract available


  11. DROZD-SOKOLOWSKA J, Waszczuk-Gajda A, Biecek P, Kobylinska K, et al
    Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy - a multicenter report by the Polish Myeloma Study Group.
    Leuk Lymphoma. 2021 Aug 16:1-9. doi: 10.1080/10428194.2021.1950712.
    PubMed     Abstract available


  12. RICHARDS H, Chavda SJ, Wilson W, Camilleri M, et al
    Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.
    Leuk Lymphoma. 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961240.
    PubMed    


    July 2021
  13. ENSSLE JC, Wolf S, von Metzler I, Weber S, et al
    High CD34 positive stem cell dosage improves thrombocyte recovery in obese myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2021 Jul 13:1-5. doi: 10.1080/10428194.2021.1950707.
    PubMed    


    June 2021
  14. CAMILLERI M, McGrath T, Wilson W, Ings SJ, et al
    Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients.
    Leuk Lymphoma. 2021 Jun 24:1-4. doi: 10.1080/10428194.2021.1941930.
    PubMed    


  15. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed     Abstract available


  16. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.
    PubMed    


  17. ZAMAGNI E, Dhanasiri S, Ghale A, Moore A, et al
    Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-b
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1924369.
    PubMed     Abstract available


    May 2021
  18. PASVOLSKY O, Shargian L, Rozovski U, Wolach O, et al
    Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation.
    Leuk Lymphoma. 2021 May 20:1-8. doi: 10.1080/10428194.2021.1929957.
    PubMed     Abstract available


  19. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.
    PubMed    


  20. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    PubMed     Abstract available


    March 2021
  21. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    PubMed     Abstract available


  22. WENGE DV, Wethmar K, Mikesch JH, Reicherts C, et al
    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
    Leuk Lymphoma. 2021 Mar 29:1-10. doi: 10.1080/10428194.2021.1894645.
    PubMed     Abstract available


  23. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021 Mar 25:1-8. doi: 10.1080/10428194.2021.1901090.
    PubMed     Abstract available


  24. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 21:1-3. doi: 10.1080/10428194.2021.1901097.
    PubMed    


  25. SHEN Y, Qi J, Wang Y, Chen J, et al
    Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors.
    Leuk Lymphoma. 2021 Mar 18:1-4. doi: 10.1080/10428194.2021.1901095.
    PubMed    


    February 2021
  26. MODI D, Albanyan O, Kim S, Deol A, et al
    Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2021 Feb 24:1-11. doi: 10.1080/10428194.2021.1891231.
    PubMed     Abstract available


    January 2021
  27. PRABAHRAN A, Koldej R, Chee L, Wong E, et al
    Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jan 31:1-13. doi: 10.1080/10428194.2021.1872072.
    PubMed     Abstract available


  28. JAIME-PEREZ JC, Hernandez-Coronado M, Picon-Galindo E, Salazar-Cavazos L, et al
    Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.
    Leuk Lymphoma. 2021 Jan 24:1-10. doi: 10.1080/10428194.2021.1876870.
    PubMed     Abstract available


    December 2020
  29. PLATE M, van Besien K
    Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2020 Dec 27:1-3. doi: 10.1080/10428194.2020.1864357.
    PubMed    


  30. MORIGI A, Casadei B, Argnani L, Stefoni V, et al
    Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-3. doi: 10.1080/10428194.2020.1855342.
    PubMed    


    November 2020
  31. VOCKOVA P, Molinsky J, Klanova M, Karban J, et al
    CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.
    Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678.
    PubMed     Abstract available


  32. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    PubMed     Abstract available


  33. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    PubMed     Abstract available


  34. FU W, Huang A, Lu G, Ni X, et al
    Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission.
    Leuk Lymphoma. 2020 Nov 11:1-8. doi: 10.1080/10428194.2020.1845340.
    PubMed     Abstract available


  35. GAUT D, Mead M
    Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Leuk Lymphoma. 2020 Nov 2:1-24. doi: 10.1080/10428194.2020.1827251.
    PubMed     Abstract available


  36. ABBOUD R, Slade M, Abboud C, DiPersio JF, et al
    Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?
    Leuk Lymphoma. 2020 Nov 2:1-3. doi: 10.1080/10428194.2020.1839657.
    PubMed    


  37. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.
    PubMed    


    October 2020
  38. LIU W, Wu M, Xie Y, Zhang C, et al
    Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-7. doi: 10.1080/10428194.2020.1834092.
    PubMed     Abstract available


  39. SINGH V, Jang H, Kim S, Ayash L, et al
    G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD.
    Leuk Lymphoma. 2020 Oct 12:1-8. doi: 10.1080/10428194.2020.1827244.
    PubMed     Abstract available


  40. HEINICKE T, Labopin M, Polge E, Stelljes M, et al
    Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
    Leuk Lymphoma. 2020 Oct 11:1-11. doi: 10.1080/10428194.2020.1827248.
    PubMed     Abstract available


  41. MOUNTJOY L, Palmer J, Kunze KL, Khera N, et al
    Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?
    Leuk Lymphoma. 2020 Oct 4:1-3. doi: 10.1080/10428194.2020.1827249.
    PubMed    


    September 2020
  42. LADHA A, Mannis G, Muffly L
    Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
    Leuk Lymphoma. 2020 Sep 29:1-7. doi: 10.1080/10428194.2020.1827247.
    PubMed     Abstract available


  43. TATARCZUCH M, Paul E, Gilberston M, Gregory GP, et al
    Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.
    Leuk Lymphoma. 2020 Sep 27:1-6. doi: 10.1080/10428194.2020.1821007.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: